tbuckley/cabot-search huggingface dataset:
Controlled release and biocompatibility of polymer/titania nanotube array system on titanium implants
Authors: Tingting Wang, Zhengyang Weng, Xiangmei Liu, Kelvin W.K. Yeung, Haobo Pan, Shuilin Wu
Journal: Bioactive Materials (2017)

Bacterial infection and tissue inflammation are the major causes of early failure of titanium-based orthopedic implants; thus, surgical implants with tunable drug releasing properties represent an appealing way to address some of these problems of bacterial infection and tissue inflammation in early age of orthopedic implants. In this work, a hybrid surface system composed of biodegradable poly(lactic-co-glycolic acid) (PLGA) and titania nanotubes (TNTs) has been successfully constructed on Ti implants with the aim of preventing bacterial infection via long-term drug release. By varying the size of the TNTs and the thickness of the polymer film, the drug release profile can be tuned to achieve the optimal therapeutic action throughout the treatment time. The size of TNTs plays a dominant role in the drug loading dose of TNTs/PLGA hybrid coatings. In this work, TNTs with an average size of 80 nm can achieve the largest loading dose. Depending on the polymer thickness, significant improvement in the drug release characteristics is attained, for instance, reduced burst release (from 84% to 27%) and overall release time extended from 5 to over 40 days. In addition, the PLGA layers may favor the proliferation and osteogenesis of MC3T3-E1 mouse cells at an earlier stage. Therefore, this TNT/PLGA hybrid surface system can be employed as an effective bioplatform for improving both self-antibacterial performance and biocompatibility of Ti-based biomaterials.
Screening for Coronary Artery Disease at an Earlier Age
Authors: Ron Blankstein, Philip Greenland
Journal: JAMA Cardiology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
Higher Rates of t(11;18) in Chinese Patients with Transformed Type of MALT Lymphoma Suggest Novel Pathways for Progression of the Disease.
Authors: Xiao-Yan Ke, Jing Wang, Ling-Zhi Zhao, Zi-Fen Gao, Fei Dong, Lin Shi, Hong-Mei Jing, Ji-Jun Wang, Wei Zhao, Xiao-Feng Yang
Journal: Blood (2007)
Ex-Vivo T Cell-Depleted Versus Unmodified Allografts in Patients with Acute Myeloid Leukemia in First Complete Remission: A Comparison of Outcomes in Two Institutions
Authors: Ulas D. Bayraktar, Marcos De Lima, Saliba M Rima, Molly Maloy, Hugo Castro-Malaspina, Julianne J Chen, Gabriela Rondon, Alexandre Chiattone, Ann A. Jakubowski, Farid Boulad, Nancy A. Kernan, Richard J. O'Reilly, Richard Champlin, Sergio A Giralt, Borje S Andersson, Esperanza B Papadopoulos
Journal: Blood (2011)
A Phase III Study to Compare Melphalan, Prednisone, Lenalidomide (MPR) Versus Melphalan 200 Mg/m2 and Autologous Transplantation (MEL200) In Newly Diagnosed Multiple Myeloma Patients
Authors: Antonio Palumbo, Federica Cavallo, Izhar Hardan, Giovannino Ciccone, Alessandra Larocca, Maide Cavalli, Jacopo Peccatori, Angelo Michele Carella, Annamaria Brioli, Anna Maria Cafro, Francesca Patriarca, Agostina Siniscalchi, Sara Pezzatti, Claudia Crippa, ittorio Montefusco, Anna Levi, Marina Ruggeri, Tommaso Caravita, Dina Ben Yehuda, Francesco Di Raimondo, Mario Boccadoro
Journal: Blood (2010)
The MMSET Protein Is Tightly Associated with Chromatin, Mediates Methylation of Specific Histone Residues and Forms a Complex with a Histone Demethylase.
Authors: Jotin Marango, Boris A. Leibovitch, Manabu Shimoyama, Hitomi Nishio, Samuel Waxman, Martin J. Walsh, Jonathan D. Licht
Journal: Blood (2006)
Prognostic Significance of BCL-2 Expression in Patients with Multiple Myeloma.
Authors: Mehmood Hashmi, Kiarash Kojouri, Jian Yang, Sunil Patel, Mohammad Khan, Nancy Sylvester-Kohrt, Rammurti Kamble, George B. Selby, Howard Ozer, Mohamed A. Kharfan-Dabaja
Journal: Blood (2004)
PDTB-11. DISRUPTING THE EPIGENETIC MODIFIER HMGA2 IN LETHAL PEDIATRIC AND ADULT GLIOMAS INHIBITS INVASION, GROWTH AND TUMORIGENICITY
Authors: Harpreet Kaur, Marianne Hütt-Cabezas, Isabella Taylor, Melanie Weingart, Fausto Rodriguez, Charles Eberhart, Eric Raabe
Journal: Neuro-Oncology (2016)

Diffuse intrinsic pontine glioma (DIPG) and glioblastoma (GBM) are highly infiltrative, incurable pediatric and adult brain tumors characterized by the presence of tumor stem-like cells. Although DIPG and GBM have different epigenetic drivers, we found increased expression of an epigenetic modifier and stem cell factor HMGA2 in both tumors by immunohistochemistry and western blotting. HMGA2 is a DNA-binding protein that regulates transcription in normal and cancer stem cells. We hypothesized that HMGA2 contributes to high grade glioma tumorigenicity through its ability to alter the transcription of many genes. Lentiviral short hairpin RNA (shRNA)-mediated reduction of HMGA2 in multiple patient-derived GBM cell lines significantly reduced invasion in transwell assay and colony formation in soft agar assay (shHMGA2 vs. shControl, P<0.01). Similarly, shRNA mediated suppression of HMGA2 in DIPG cell lines reduced proliferation (BrdU incorporation), reduced invasion (transwell assay) and increased apoptosis (cleaved caspase-3 immunofluorescence, shHMGA2 vs. shControl, P<0.001). Pharmacological inhibition of HMGA proteins using the DNA minor-groove binding drug Netropsin significantly inhibited proliferation and increased apoptosis of DIPG cell lines (P<0.01). Mice bearing orthotopic GBM xenografted cells transduced with HMGA2 shRNA lived significantly longer (108 days) compared to control shRNA (67.5 days, P<0.0001 by log-rank analysis). To investigate the mechanism of HMGA2-mediated malignancy, we discovered high levels of CD44 (a known mediator of invasion and stemness) that correlated with high HMGA2 expression in DIPG and GBM tumors. Suppression of HMGA2 led to decreased CD44 protein expression. Knockdown of CD44 in HMGA2-high DIPG and GBM neurospheres reduced invasion and proliferation (P<0.01). Our studies suggest an oncogenic role of HMGA2 and its downstream effectors in gliomas and identify this important pathway as a potential therapeutic target. We conclude that minor groove binding agents similar to Netropsin may be effective agents for HMGA2-expressing pediatric and adult high grade gliomas.
Rituximab (Rituxan) Combined with ESHAP Chemotherapy Is Highly Active in Relapsed/ Refractory Aggressive Non-Hodgkin’s Lymphoma.
Authors: Parameswaran Venugopal, Stephanie A. Gretory, John Showel, Jamile Shammo, Sari Enschede, Melissa Larson, Teresa Obrien, Tatiana D. Sokolovsky, Aaron Means
Journal: Blood (2004)
A distinct innate lymphoid cell population regulates tumor-associated T cells
Authors: Sarah Q Crome, Linh T Nguyen, Sandra Lopez-Verges, S Y Cindy Yang, Bernard Martin, Jennifer Y Yam, Dylan J Johnson, Jessica Nie, Michael Pniak, Pei Hua Yen, Anca Milea, Ramlogan Sowamber, Sarah Rachel Katz, Marcus Q Bernardini, Blaise A Clarke, Patricia A Shaw, Philipp A Lang, Hal K Berman, Trevor J Pugh, Lewis L Lanier, Pamela S Ohashi
Journal: Nature Medicine (2017)
SURG-13. STIMULATED RAMAN SCATTERING MICROSCOPY PROVIDES DIAGNOSTIC INTRAOPERATIVE HISTOPATHOLOGIC IMAGES IN BRAIN TUMOR PATIENTS
Authors: Daniel A. Orringer, Balaji Pandian, Todd C. Hollon, Yashar S. Niknafs, Julianne Boyle, Spencer Lewis, Shawn L. Hervey-Jumper, Hugh J.L. Garton, Cormac O. Maher, Jason A. Heth, Oren Sagher, Matija Snuderl, Sriram Venneti, Shakti Ramkissoon, Kathryn A. McFadden, Amanda Fisher-Hubbard, Andrew Lieberman, Timothy D. Johnson, X. Sunney Xie, Christian W. Freudiger, Sandra Camelo-Piragua
Journal: Neuro-Oncology (2016)

Accurate histologic information is essential to decision-making during brain tumor surgery. Current methods of intraoperative histopathologic diagnosis are labor intensive, prone to artifacts that complicate interpretation, and may delay surgical care. Stimulated Raman scattering (SRS) microscopy, a label-free optical process, presents an opportunity for rapid intraoperative histopathologic imaging as it has recently been shown to detect brain tumor infiltration in fresh, unprocessed human surgical specimens. Until now, execution of SRS microscopy in a clinical setting has not been possible. Here, we report the first demonstration of SRS microscopy in an operating room using a portable, fully-integrated fiber-laser-based SRS microscope in a series of fresh, unprocessed specimens from 97 neurosurgical patients. Additionally, we leverage 2-channel SRS images to generate virtual hematoxylin and eosin-stained images, revealing microscopic architectural features essential for the diagnosis of human brain tumors. In a simulation of intraoperative pathologic consultation completed by three board-certified neuropathologists, the concordance of SRS- and standard H&E-based methods for predicting diagnosis was nearly perfect (k>0.89) and the accuracy exceeded 92% for both methods. A multi-layer perceptron based on quantified attributes from SRS images was capable of predicting brain tumor subtype with 86.6% accuracy in a test set of 30 patients. SRS microscopy provides a simple, automated method for rapidly providing diagnostic histopathologic images in the operating room, without the need for processing, preparation, and staining tissue specimens in a pathology lab. SRS microscopy may ultimately enable more thorough histologic sampling of brain tumors and meticulous assessment of their interface with surrounding brain tissue during surgery.
Utility of the modified Glasgow prognostic score in patients with metastatic renal cell carcinoma treated with targeted agents.
Authors: Mikhail Y. Akbashev, Brian Michael Lingerfelt, Yuan Liu, Omer Kucuk, Viraj A. Master, Wayne Harris
Journal: Journal of Clinical Oncology (2012)

441 Background: The modified Glasgow prognostic score (mGPS) is a pre-treatment prognostic system based on inflammatory biomarkers that is comparable in accuracy to the Memorial Sloan-Kettering Cancer Center (MSKCC) score for patients with metastatic renal cell carcinoma (mRCC) treated with cytokines. However, data are limited regarding the current utility of prognostic models developed in the cytokine era. In this study we examined the correlation between pre-treatment and post-treatment mGPS values and clinical benefit response (CBR) in patients treated with targeted agents for mRCC. Methods: After obtaining approval from the Emory Institutional Review Board, mGPS values were determined retrospectively using published methods and measurements of serum C-reactive protein (CRP) and serum albumin from patients who received targeted therapy for mRCC of any histology at the Emory Winship Cancer Institute between January 1, 2005 and June 30, 2011. CBR was defined as complete response (CR), partial response (PR) and stable disease (SD). Inclusion criteria included availability of at least 3 CRP values per patient. Results: Of the 635 patients who were screened, 56 were found to meet inclusion criteria. Of these, 43 received one evaluable line(s) of therapy (ELOT), 9 received two, 3 received three and 1 received four. The 74 ELOT included temsirolimus (16), sunitinib (20), sorafenib (14), pazopanib (20), everolimus (3) and bevacizumab/interferon (1). The correlation of post-treatment mGPS values to CBR was greater than pre-treatment mGPS values with sensitivity (81%), specificity (87%), positive predictive value (85%) and negative predictive value (83%). The p values were &lt;0.001 for each parameter. Conclusions: Although these data require prospective validation, they provide evidence for the prognostic utility of mGPS assessments before and after therapy with targeted agents. Of note, the likelihood of having a CBR was much greater in patients who achieved or maintained an mGPS value of 0 after therapy. If confirmed, serial assessments of the mGPS to determine inflammatory response rates may prove to be a valuable and cost effective tool for patient care and drug development in mRCC.
Comparison of Outcomes in Elderly Patients with Non-Hodgkins Lymphoma Undergoing High-Dose Chemotherapy to Their Younger Counterparts: Greater Morbidity but No Significant Impact on Overall Survival.
Authors: Tanya M. Wildes, Kristan M. Augustin, Ravi Vij, Nancy Bartlett, John F. DiPersio, Steven M. Devine
Journal: Blood (2005)
Prognostic Significance of Tissue Necrosis Factor-Alpha in Newly Diagnosed Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes.
Authors: Apostolia-Maria Tsimberidou, Elihu Estey, Maher Albitar, Sijin Wen, Mark Brandt, Sherry Pierce, Hagop Kantarjian, Razelle Kurzrock
Journal: Blood (2007)
Pseudogenization of the Secreted Effector Gene sseI Confers Rapid Systemic Dissemination of S. Typhimurium ST313 within Migratory Dendritic Cells
Authors: Sarah E. Carden, Gregory T. Walker, Jared Honeycutt, Kyler Lugo, Trung Pham, Amanda Jacobson, Donna Bouley, Juliana Idoyaga, Renee M. Tsolis, Denise Monack
Journal: Cell Host & Microbe (2017)
Long-Term Remission Maintenance on Weekly Imatinib Dosage In Patients with FIP1L1-PDGFRA-Positive Chronic Eosinophilic Leukaemia
Authors: Grzegorz Helbig, Marek Hus, Andrzej Moskwa, Krystyna Zawilska, Lucyna Molendowicz-Portala, Alina Świderska, Alina Urbanowicz, Ewa &dot;Zuk, Małgorzata Raźny, Marek Rodzaj, Ilona Seferyńska, Małgorzata Całbecka, Ryszard Wichary, Slawomira Kyrcz-Krzemien
Journal: Blood (2010)
Abstract 14451: High Agreement Between a Cardiology Specific Scoring System and the ACMG Criteria for Genetic Variant Interpretation and Classification
Authors: Tomas Robyns, Cuno Kuiperi, Rik Willems, Johan Van Cleemput, Dieter Nuyens, Jeroen Breckpot, Gert Matthijs, Anniek Corveleyn
Journal: Circulation (2016)

Introduction: The assessment of pathogenicity of genetic sequence variants is probabilistic and remains a challenge. Recently a consensus recommendation for genetic variant interpretation and class...
Epigenetic regulation and tumorigenicity of ovarian cancer cells.
Authors: F. Meng, G. Sun, M. Zhong, Y. Yu, M. Brewer
Journal: Journal of Clinical Oncology (2011)

e15546 Background: Ovarian cancer typically has an excellent response to chemotherapy but has a high rate of recurrence with patients ultimately dying from chemoresistance. The objective of this study was to investigate the relationship between histone modification, DNA methylation and DNA damage repair response that occur in platinum resistant ovarian cancer cell lines treated with epigenetic modifiers in combination with low dose cisplatin to develop new approaches for chemotherapy resistant ovarian cancer. Methods: We selected two common epigenetic modifiers Trichostain A (TSA), a histone deacetylase inhibitor and 5-aza-2'-deoxycytidine (decitabine), a demethylating agent which were evaluated alone and in combination with low dose cisplatin for their tumorigencity in SCID mice and their spheroid formation in serum-free medium with two ovarian cancer cell lines SKOV3 and Hey. We also measured the effect of these drugs on tumor suppression pathways, AKT pathway, and expression of cadherins as well as histone modification. Results: All combinations of TSA, decitabine and cisplatin inhibited both tumorigenicity and spheroid formation in both cell lines with Hey exhibiting more resistance to treatment. E-cadherin expression was suppressed in SKOV3 cells while N-caderin expression was suppressed in Hey cells with both TSA and cisplatin and decitabine and cisplatin. In the Hey cell line, p53 expression was increased by sequential treatment with low dose decitabine and low dose cisplatin and by low dose TSA and low dose cisplatin. The profiling of histone code revealed distinctly different chromatin regulation between Hey cells and SKOV3 cells. The expression patterns and characteristics of cell adhesion, mutiple-drug transporter, apoptosis are distinctly different in these two ovarian cancer cell lines, which may be due to the different origins and stages of these cell lines. Conclusions: The combinations of decitabine, TSA and cisplatin suppressed the formation and growth of xenograft and tumor spheroid, altered the molecular mechanism of cell adhesion, chemosensitivity, and chromatin modification which may provide a new and promising treatment strategy for chemoresistant ovarian cancer.
Dyskeratosis Congenita: Evaluation of Immune Status and Hematopoietic Stem Cell Transplantation. A Literature and EBMT Data Base Survey of 75 Patients,
Authors: Elisabeth T Korthof, Judith Van der Zalm, Martine F Raphael, Dorine Bresters, Jakub Tolar, Mahmoud Aljurf, Paul Veys, Rosi Oneto, Andrea Bacigalupo, Christina Peters, Bobby Gaspar, Carlo Dufour, Judith C. W. Marsh
Journal: Blood (2011)
Ethylene Diamine Tetra Acetic Acid (EDTA) Decalcification of Paediatric Bone Marrow Trephines In a Diagnostic Laboratory
Authors: Shriram Vaidia Nath, Michelle Tamblyn, Susan Telfer, Tony Henwood, Peter Gilham, Colin Story, Greg Hodge, Akash Kalro, Michael Osborn, Ram Suppiah, Heather Tapp, Ian C Nicholson, Heddy Zola, Sarah Moore, Andrew Zannettino, Nick Manton, Tamas Revesz
Journal: Blood (2010)
Long Intergenic Non-Coding RNAs (lincRNA) Impacts Biology and Clinical Outcome in Multiple Myeloma
Authors: Mehmet Kemal Samur, Naim Rashid, Alice Cleynen, Mariateresa Fulciniti, Adam Sperling, Stephane Minvielle, Kenneth C. Anderson, Giovanni Parmigiani, Hervé Avet-Loiseau, Nikhil C. Munshi
Journal: Blood (2014)
Updated Efficacy and Safety from the Phase 3 Resonate-2 Study: Ibrutinib As First-Line Treatment Option in Patients 65 Years and Older with Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia
Authors: Paul Barr, Tadeusz Robak, Carolyn J Owen, Alessandra Tedeschi, Osnat Bairey, Nancy L Bartlett, Jan Burger, Peter Hillmen, Steven Coutre, Stephen Devereux, Sebastian Grosicki, Helen McCarthy, Jianyong Li, David Simpson, Fritz Offner, Carol Moreno, Cathy Zhou, Lori Styles, Danelle F. James, Thomas J. Kipps, Paolo Ghia
Journal: Blood (2016)
Hypoxia determines survival outcomes of bacterial infection through HIF-1α–dependent reprogramming of leukocyte metabolism
Authors: A. A. Roger Thompson, Rebecca S. Dickinson, Fiona Murphy, John P. Thomson, Helen M. Marriott, Adriana Tavares, Joseph Willson, Lynne Williams, Amy Lewis, Ananda Mirchandani, Patricia Dos Santos Coelho, Catherine Doherty, Eilise Ryan, Emily Watts, Nicholas M. Morton, Shareen Forbes, Roland H. Stimson, Abdul G. Hameed, Nadine Arnold, Julie A. Preston, Allan Lawrie, Veronica Finisguerra, Massimiliano Mazzone, Pranvera Sadiku, Jermaine Goveia, Federico Taverna, Peter Carmeliet, Simon J. Foster, Edwin R. Chilvers, Andrew S. Cowburn, David H. Dockrell, Randall S. Johnson, Richard R. Meehan, Moira K. B. Whyte, Sarah R. Walmsley
Journal: Science Immunology (2017)

Infection outcomes are regulated by neutrophil responses to oxygen and nutrient availability.
Targeting Mcl-1 for Multiple Myeloma (MM) Therapy: Drug-Induced Generation of Mcl-1 Fragment Mcl-1128–350 Triggers MM Cell Death Via c- Jun Upregulation
Authors: Fengjuan Fan, Giovanni Tonon, Martin Sattler, Alexander Schimming, Hartmut Goldschmidt, Joseph Opferman, Kenneth C. Anderson, Dirk Jaeger, Klaus Podar
Journal: Blood (2012)
gastrointestinal tumours, colorectal Nintedanib plus best supportive care (BSC) versus placebo plus BSC for the treatment of patients (pts) with colorectal cancer (CRC) refractory to standard therapies: Results of the phase III LUME-colon 1 study
Authors: E. Van Cutsem, T. Yoshino, H.-J. Lenz, S. Lonardi, A. Falcone, M.L. Limon, M.P. Saunders, A. Sobrero, E. Maiello, Y.S. Park, R. Ferreiro Monteagudo, Y.S. Hong, J. Tomasek, H. Taniguchi, F. Ciardiello, J. Hocke, Z. Oum'hamed, S. Vlassak, M. Studeny, J. Tabernero
Journal: Annals of Oncology (2016)
Increasing Clinical Peanut Thresholds Through Immunotherapy: Quantitative Assessment of the Safety Benefits Associated with Achieving a 300 or 1000 mg Peanut Protein Threshold.
Authors: Joseph L. Baumert, Charles Ruban, Laurent R. Martin, Thebault Claude, Luis M. Salmun, Stephen L. Taylor, Stef Koppelman
Journal: Journal of Allergy and Clinical Immunology (2017)
An elevated fibrinogen/CRP ratio predicts a remarkable survival advantage in patients with metastatic pancreatic cancer
Authors: T. Winder, F. Posch, E. Asamer, M. Stotz, A. Siebenhüner, K. Schlick, T. Magnes, P. Samaras, J. Szkandera, P.-A. Clavien, D. Neureiter, R. Greil, B.C. Pestalozzi, H. Stoeger, A. Gerger, A. Egle, M. Pichler
Journal: Annals of Oncology (2016)
Translocation t(4;14) Is Not an Adverse Prognostic Factor in Patients with Multiple Myeloma Undergoing Allogeneic Stem Cell Transplantation.
Authors: Timon Hansen, Georgia Schilling, Avichai Shimoni, Jose-Antonio Simon-Perez, Wolfgang Bethge, Peter Liebisch, Rainer Schwerdtfeger, Martin Bornhaeuser, Svenja Otterstetter, Francis Ayuk, Carsten Bokemeyer, Axel R. Zander, Jesus San-Miguel, Arnon Nagler, Nicolaus Kroeger
Journal: Blood (2007)
Vitamin D3-Mediated Regulation of the Antimicrobial Peptides CAMP and DEFB4 Is Evolutionarily Important for Innate Immunity in Humans and Primates.
Authors: Adrian F. Gombart, Hong Chen, Lisbet Brandi, Klaus Olgaard, Niels Borregaard, John S. Adams, H. Phillip Koeffler
Journal: Blood (2005)
Uncovering Thalidomide Mechanism of Action: Neuropilin 1 Represents the Target of Antiangiogenic and Immunomodulatory Effect in Chronic Lymphocytic Leukemia
Authors: Krzysztof Giannopoulos, Marcin Omiotek, Kamila Kosior, Radoslaw Mlak, Malgorzata Kowal, Jacek M. Rolinski, Hartmut Dohner, Stephan Stilgenbauer, Anna Dmoszynska, Lars Bullinger
Journal: Blood (2011)
The association of physical performance tests with injury in collegiate athletes
Authors: Eric J Hegedus
Journal: British Journal of Sports Medicine (2017)

### What did I do?

The first aim of my PhD involved reviewing the literature to determine whether common, established physical performance tests demonstrated predictive validity with regard to lower extremity injuries in athletic populations.

The second aim was to prospectively examine the association of physical performance tests performed in the preseason with injury acquired during the season.

### Why did I do it?

As a clinician scientist, it is my personal belief, and one shared with others,1 2 that injury is best explained by a dynamic systems model. Within this model, there are numerous inter-related variables such that the change in one variable affects all other variables. As I spoke with clinicians, an increasing number were speaking with certainty that asymmetry on slowly performed tests was predictive of injury. This simple mechanism of testing did not seem to fit with the …